Get started
Author

Olga Abramczyk

Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival
2012 · Luke R. G. Pike, Dean C. Singleton, et al. · Biochemical Journal · 160
PDF
Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 To Regulate Its Activity and Calcium Dependence
2012 · Clint D. J. Tavares, John P. O’Brien, et al. · Biochemistry · 63
Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact
2012 · Ashwini K. Devkota, Clint D. J. Tavares, et al. · Biochemistry · 61
The Anti-Apoptotic Protein PEA-15 Is a Tight Binding Inhibitor of ERK1 and ERK2, Which Blocks Docking Interactions at the D-Recruitment Site
2007 · Kari Callaway, Olga Abramczyk, et al. · Biochemistry · 57
Phosphorylation of NDRG1 is temporally and spatially controlled during the cell cycle
2011 · Catherine McCaig, Louisa Potter, et al. · Biochemical and Biophysical Research Communications · 47
Properties and Regulation of a Transiently Assembled ERK2·Ets-1 Signaling Complex
2006 · Kari A. Callaway, Mark A. Rainey, et al. · Biochemistry · 47
Solution NMR Insights into Docking Interactions Involving Inactive ERK2
2011 · Andrea Piserchio, Mangalika Warthaka, et al. · Biochemistry · 44
Activated ERK2 Is a Monomer in Vitro with or without Divalent Cations and When Complexed to the Cytoplasmic Scaffold PEA-15
2011 · Tamer S. Kaoud, Ashwini K. Devkota, et al. · Biochemistry · 40
Expanding the Repertoire of an ERK2 Recruitment Site: Cysteine Footprinting Identifies the D-Recruitment Site as a Mediator of Ets-1 Binding
2007 · Olga Abramczyk, Mark A. Rainey, et al. · Biochemistry · 37
Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells
2012 · Hiu-Fung Yuen, Olga Abramczyk, et al. · Bioscience Reports · 33
PDF
Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli
2011 · Olga Abramczyk, Clint D.J. Tavares, et al. · Protein Expression and Purification · 28
The protein kinase 60S is a free catalytic CK2α′ subunit and forms an inactive complex with superoxide dismutase SOD1
2003 · Olga Abramczyk, Piotr Zień, et al. · Biochemical and Biophysical Research Communications · 22
TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications
2003 · Piotr Zień, Olga Abramczyk, et al. · Biochemical and Biophysical Research Communications · 17
Corrigendum to “Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli” [Protein Expression and Purification 79 (2011) 237–244]
2012 · Olga Abramczyk, Clint D.J. Tavares, et al. · Protein Expression and Purification · 2
Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action
2024 · Krysztof Lacek, Anna Jablonska, et al. · Cancer Research · 1
Abstract 3080: Site-specific conjugation of CPL976H-MMAE enables stable and selective dual targeting of PD-L1 and AXL
2026 · Delfina Popiel, Filip Mitula, et al. · Cancer Research
Development of Bispecific Antibody Targeting Human IL-17A and IL-6
2026 · Beata Pamuła, Martyna Banach, et al. · Antibodies
PDF
Abstract 3105: Unveiling the potential of humanized bispecific antibody: a novel approach to tumor suppression in oncology
2025 · Anna Jablonska, Damian Kolakowski, et al. · Cancer Research
Abstract 5084: A first-in-class bispecific antibody CPL976 with a dual PD-L1/AXL mechanism of action that promotes common biological antitumor effects in in vitro and in vivo models
2024 · Delfina Popiel, Damian Kołakowski, et al. · Cancer Research
Abstract B121: CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic
2023 · Agnieszka Bojko-Matuszek, Damian Kołakowski, et al. · Molecular Cancer Therapeutics
Abstract B146: Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecific antibody conjugated with MMAE in targeted anticancer therapy
2023 · Delfina Popiel, Krzysztof Lacek, et al. · Molecular Cancer Therapeutics
Design and development of an innovative, safe, and highly potent E1 ubiquitin-activating enzyme inhibitor CPL–410-005 conjugate in anticancer therapy
2022 · F. Mituła, M. Równicki, et al. · European Journal of Cancer
Yeast Cu, Zn-superoxide dismutase [SOD] as an inhibitory subunit of protein kinase CK2alpha'
2003 · Raymond E. Zielinski, Olga Abramczyk, et al.
Works count: 23
Citation count: 659
H-index: 13
I10-index: 13
Year
Topic
Type